NCT04170829View on ClinicalTrials.gov

A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 17, 2019

Primary Completion Date

November 26, 2020

Study Completion Date

November 26, 2020

Conditions
Middle East Respiratory Syndrome Coronavirus
Interventions
BIOLOGICAL

ChAdOx1 MERS

a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.

Trial Locations (1)

11426

King Abdulaziz Medical City, National Guard Health Affairs, Riyadh

All Listed Sponsors
collaborator

University of Oxford

OTHER

lead

King Abdullah International Medical Research Center

OTHER

NCT04170829 - A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002) | Biotech Hunter | Biotech Hunter